Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 41-55

  Ryan, Caitriona ^a   Kirby, Brian ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cardiovascular; Comorbidities; Diabetes; Metabolic syndrome; Myocardial infarction; Obesity; Psoriasis; Smoking

Indexed keywords

ADIPOCYTOKINE; CYCLOSPORIN; ESTER DERIVATIVE; ETRETIN; FUMARIC ACID DERIVATIVE; FUMARIC ACID ESTER DERIVATIVE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL ABUSE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOGENESIS; METABOLIC DISORDER; METABOLIC SYNDROME X; MORTALITY; NEPHROTOXICITY; NONHUMAN; OBESITY; PATIENT EDUCATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK MANAGEMENT; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC THERAPY; THERAPY EFFECT; ALCOHOLISM; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; INFLAMMATION; METABOLISM; RISK FACTOR;

ACITRETIN; ADIPOKINES; ALCOHOLISM; ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIOVASCULAR DISEASES; COMORBIDITY; CYCLOSPORINE; DERMATOLOGIC AGENTS; DIABETES MELLITUS; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; METABOLIC SYNDROME X; METHOTREXATE; OBESITY; PSORIASIS; RISK FACTORS; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911495644     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.004     Document Type: Review

References (127)

1. Gelfand J.M., Troxel A.B., Lewis J.D., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007, 143:1493-1499.
2. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741.
3. Henseler T., Christophers E. Disease concomitance in psoriasis. JAm Acad Dermatol 1995, 32:982-986.
4. McDonald C.J., Calabresi P. Occlusive vascular disease in psoriatic patients. NEngl J Med 1973, 288:912.
5. Kaye J.A., Li L., Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008, 159:895-902.
6. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19:225-230.
7. Armstrong E.J., Harskamp C.T., Armstrong A.W. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. JAm Heart Assoc 2013, 2:e000062.
8. Abuabara K., Azfar R.S., Shin D.B., et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010, 163:586-592.
9. Wakkee M., Herings R.M., Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. JInvest Dermatol 2010, 130:962-967.
10. Stern R.S., Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. JInvest Dermatol 2011, 131:1159-1166.
11. Gelfand J.M., Mehta N.N., Langan S.M. Psoriasis and cardiovascular risk: strength in numbers, part II. JInvest Dermatol 2011, 131:1007-1010.
12. Gisondi P., Fantin F., Del Giglio M., et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009, 218:110-113.
13. Ludwig R.J., Herzog C., Rostock A., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007, 156:271-276.
14. Akyildiz Z.I., Seremet S., Emren V., et al. Epicardial fat thickness is independently associated with psoriasis. Dermatology 2014, 228:55-59.
15. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. JHypertens 2013, 31:433-442. [discussion: 442-3].
16. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013, 149:84-91.
17. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007, 167:1670-1675.
18. Mallbris L., Granath F., Hamsten A., et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. JAm Acad Dermatol 2006, 54:614-621.
19. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005, 141:1527-1534.
20. Available at: . Accesssed 29 June, 2014. http://www.clinicaltrials.gov/ct2/show/NCT00879944?term=pediatric+psoriasis%26rank=3.
21. Paller A.S., Mercy K., Kwasny M.J., et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol 2013, 149:166-176.
22. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
23. Sommer D.M., Jenisch S., Suchan M., et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006, 298:321-328.
24. Grundy S.M., Brewer H.B., Cleeman J.I., American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
25. Langan S.M., Seminara N.M., Shin D.B., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. JInvest Dermatol 2012, 132:556-562.
26. Goldminz A.M., Buzney C.D., Kim N., et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol 2013, 30:700-705.
27. Wu S., Li W.Q., Han J., et al. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol 2014, 66:304-310.
28. Yu Y., Sheth N., Krishnamoorthy P., et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis 2012, 2:285-292.
29. Mehta N.N., Li R., Krishnamoorthy P., et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012, 224:218-221.
30. Holzer M., Wolf P., Curcic S., et al. Psoriasis alters HDL composition and cholesterol efflux capacity. JLipid Res 2012, 53:1618-1624.
31. Holzer M., Wolf P., Inzinger M., et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. JInvest Dermatol 2014, 134:635-642.
32. Behnam S.M., Behnam S.E., Koo J.Y. Smoking and psoriasis. Skinmed 2005, 4:174-176.
33. Wolk K., Mallbris L., Larsson P., et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009, 89:492-497.
34. Poikolainen K., Karvonen J., Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999, 135:1490-1493.
35. McAleer M.A., Mason D.L., Cunningham S., et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 2011, 164:1256-1261.
36. Armstrong A.W., Harskamp C.T., Dhillon J.S., et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol 2014, 170:304-314.
37. Torii K., Saito C., Furuhashi T., et al. Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients. Exp Dermatol 2011, 20:371-373.
38. Matsumoto C., Miedema M.D., Ofman P., et al. An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. JCardiopulm Rehabil Prev 2014, 34(3):159-171.
39. Dreiher J., Weitzman D., Shapiro J., et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 2008, 159:956-960.
40. Tobin A.M., Hughes R., Hand E.B., et al. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clin Exp Dermatol 2011, 36:19-23.
41. Schmitt J., Ford D.E. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach. Gen Hosp Psychiatry 2007, 29:134-140.
42. Charlson F.J., Moran A.E., Freedman G., et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med 2013, 11:250.
43. Ryan C., Menter A. Psoriasis and cardiovascular disorders. GItal Dermatol Venereol 2012, 147:179-187.
44. Davidovici B.B., Sattar N., Prinz J.C., et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. JInvest Dermatol 2010, 130:1785-1796.
45. Gisondi P., Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009, 35:313-324.
46. Armstrong A.W., Voyles S.V., Armstrong E.J., et al. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. JDermatol Sci 2011, 63:1-9.
47. Boehncke W.H., Boehncke S., Tobin A.M., et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011, 20:303-307.
48. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
49. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
50. Hashmi S., Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006, 17:699-706.
51. Wang Z., Lee J., Zhang Y., et al. Increased Th17 cells in coronary artery disease are associated with neutrophilic inflammation. Scand Cardiovasc J 2011, 45:54-61.
52. Wyss C.A., Neidhart M., Altwegg L., et al. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 2010, 31:1457-1469.
53. Cheng X., Yu X., Ding Y.J., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97.
54. Chen S., Crother T.R., Arditi M. Emerging role of IL-17 in atherosclerosis. JInnate Immun 2010, 2:325-333.
55. Xie J.J., Wang J., Tang T.T., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010, 49:185-193.
56. Eid R.E., Rao D.A., Zhou J., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
57. Taleb S., Romain M., Ramkhelawon B., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. JExp Med 2009, 206:2067-2077.
58. Wang M., Zhang W., Crisostomo P., et al. Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling. Am J Physiol Heart Circ Physiol 2007, 293:H2101-H2108.
59. Mehta N.N., Li K., Szapary P., et al. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. JTransl Med 2013, 11:194.
60. Rasouli N., Kern P.A. Adipocytokines and the metabolic complications of obesity. JClin Endocrinol Metab 2008, 93:S64-S73.
61. Chen Y.J., Wu C.Y., Shen J.L., et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008, 144:1571-1575.
62. Spranger J., Kroke A., Möhlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
63. Hulthe J., Hultén L.M., Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003, 52:1612-1614.
64. Zhang Y., Proenca R., Maffei M., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
65. Tartaglia L.A. The leptin receptor. JBiol Chem 1997, 272:6093-6096.
66. Bouloumié A., Drexler H.C., Lafontan M., et al. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998, 83:1059-1066.
67. Frank S., Stallmeyer B., Kämpfer H., et al. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. JClin Invest 2000, 106:501-509.
68. Cerman A.A., Bozkurt S., Sav A., et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008, 159:820-826.
69. Hamminga E.A., van der Lely A.J., Neumann H.A., et al. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006, 67:768-773.
70. Trayhurn P. The biology of obesity. Proc Nutr Soc 2005, 64:31-38.
71. Wang Y., Chen J., Zhao Y., et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008, 158:1134-1135.
72. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004, 316:924-929.
73. Okamoto Y., Kihara S., Funahashi T., et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267-278.
74. Kaur S., Zilmer K., Kairane C., et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008, 159:1364-1367.
75. Coimbra S., Oliveira H., Reis F., et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. JDermatol Sci 2009, 55:202-204.
76. Shibata S., Saeki H., Tada Y., et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. JDermatol Sci 2009, 55:62-63.
77. Takahashi H., Tsuji H., Takahashi I., et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008, 159:1207-1208.
78. Li R.C., Krishnamoorthy P., DerOhannessian S., et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol 2014, 39:19-24.
79. Curat C.A., Wegner V., Sengenès C., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
80. Filková M., Haluzík M., Gay S., et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009, 133:157-170.
81. Chu S., Ding W., Li K., et al. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008, 72:1249-1253.
82. Reilly M.P., Lehrke M., Wolfe M.L., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
83. Johnston A., Arnadottir S., Gudjonsson J.E., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008, 159:342-350.
84. Boehncke S., Thaci D., Beschmann H., et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007, 157:1249-1251.
85. Yang Q., Graham T.E., Mody N., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
86. Rollman O., Vahlquist A. Psoriasis and vitamin A. Plasma transport and skin content of retinol, dehydroretinol and carotenoids in adult patients versus healthy controls. Arch Dermatol Res 1985, 278:17-24.
87. Takeshita J., Mohler E.R., Krishnamoorthy P., et al. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. JAm Heart Assoc 2014, 3:e000507.
88. Tamagawa-Mineoka R., Katoh N., Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. JAm Acad Dermatol 2010, 62:621-626.
89. Pelletier F., Garnache-Ottou F., Angelot F., et al. Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. JInvest Dermatol 2011, 131:1573-1576.
90. Rautou P.E., Leroyer A.S., Ramkhelawon B., et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011, 108:335-343.
91. Kasperska-Zajac A., Brzoza Z., Rogala B. Platelet function in cutaneous diseases. Platelets 2008, 19:317-321.
92. Hayashi S., Shimizu I., Miyauchi H., et al. Increased platelet aggregation in psoriasis. Acta Derm Venereol 1985, 65:258-262.
93. Ludwig R.J., Schultz J.E., Boehncke W.H., et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. JInvest Dermatol 2004, 122:830-836.
94. Nielsen H.J., Christensen I.J., Svendsen M.N., et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002, 51:563-567.
95. Friedewald V.E., Cather J.C., Gelfand J.M., et al. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008, 102:1631-1643.
96. Strohal R., Kirby B., Puig L., the Psoriasis Expert Panel (Girolomoni G, Kragballe K, Luger T, Nestle FO, Prinz JC, Ståhle M, Yawalkar N) Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. Eur J Dermatol 2014, 305-311. [Epub ahead of print].
97. Mehta N.N., Yu Y., Pinnelas R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011, 124:775.e1-775.e6.
98. Higa-Sansone G., Szomstein S., Soto F., et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004, 14:1132-1134.
99. Wolters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005, 153:706-714.
100. Naldi L., Conti A., Cazzaniga S., et al. Diet and physical exercise in psoriasis. A randomized trial. Br J Dermatol 2013, 170(3):634-642.
101. Gisondi P., Del Giglio M., Di Francesco V., et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008, 88:1242-1247.
102. Roongpisuthipong W., Pongpudpunth M., Roongpisuthipong C., et al. The effect of weight loss in obese patients with chronic stable plaque-type psoriasis. Dermatol Res Pract 2013, 2013:795932.
103. Sigurdardottir G., Ekman A.K., Ståhle M., et al. Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis. JAm Acad Dermatol 2014, 70(6):1067-1075.
104. Gerdes S., Osadtschy S., Buhles N., et al. Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol 2014, 23(5):322-325.
105. Silva D., Pais de Lacerda A. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. Rev Port Cardiol 2012, 31:733-745. [in Portuguese].
106. Chandran V., Cook R.J., Edwin J., et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010, 49:1399-1405.
107. Coimbra S., Oliveira H., Reis F., et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. JEur Acad Dermatol Venereol 2010, 24:789-796.
108. Yurtdaş M., Yaylali Y.T., Kaya Y., et al. Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. Echocardiography 2014, 31(9):1095-1104.
109. Cao L.Y., Soler D.C., Debanne S.M., et al. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions. Am J Transl Res 2013, 6:16-27.
110. Boehncke S., Salgo R., Garbaraviciene J., et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. JEur Acad Dermatol Venereol 2011, 25(10):1187-1193.
111. Wu J.J., Poon K.Y., Channual J.C., et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012, 148:1244-1250.
112. Prodanovich S., Prodanowich S., Ma F., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. JAm Acad Dermatol 2005, 52:262-267.
113. Available at: . Accessed March 31, 2014. http://clinicaltrials.gov/ct2/show/NCT01594333?term=NCT01594333%26rank=1.
114. Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II. JAm Acad Dermatol 2010, 63:949-972. [quiz: 973-4].
115. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. JAm Acad Dermatol 2009, 61:451-485.
116. Vahlquist A. Long-term safety of retinoid therapy. JAm Acad Dermatol 1992, 27:S29-S33.
117. Mrowietz U., Rostami-Yazdi M., Neureither M., et al. 15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris. JDtsch Dermatol Ges 2009, 7(Suppl 2):S3-S16. [in German].
118. Boehncke S., Fichtlscherer S., Salgo R., et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2011, 303:381-388.
119. Ahlehoff O., Skov L., Gislason G., et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory0 drugs: a Danish real-world cohort study. JIntern Med 2013, 273:197-204.
120. Strober B., Teller C., Yamauchi P., et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008, 159:322-330.
121. Kanelleas A., Liapi C., Katoulis A., et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol 2011, 36(8):845-850.
122. Solomon D.H., Massarotti E., Garg R., et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305:2525-2531.
123. Ryan C., Leonardi C.L., Krueger J.G., et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011, 306:864-871.
124. Tzellos T., Kyrgidis A., Zouboulis C.C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. JEur Acad Dermatol Venereol 2013, 27:622-627.
125. Dommasch E.D., Troxel A.B., Gelfand J.M. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. JAm Acad Dermatol 2013, 68:863-865.
126. Greenland S., Salvan A. Bias in the one-step method for pooling study results. Stat Med 1990, 9:247-252.
127. Papp K.A., Griffiths C.E., Gordon K., et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013, 168:844-854.